Your browser doesn't support javascript.
loading
Identification of a highly potent and selective CB2 agonist, RQ-00202730, for the treatment of irritable bowel syndrome.
Iwata, Yasuhiro; Ando, Kazuo; Taniguchi, Kana; Koba, Naomi; Sugiura, Akemi; Sudo, Masaki.
Afiliación
  • Iwata Y; Research and Development, RaQualia Pharma Inc, 5-2 Taketoyo, Aichi 470-2341, Japan. Electronic address: yasuhiro.iwata@raqualia.com.
  • Ando K; Research and Development, RaQualia Pharma Inc, 5-2 Taketoyo, Aichi 470-2341, Japan.
  • Taniguchi K; Research and Development, RaQualia Pharma Inc, 5-2 Taketoyo, Aichi 470-2341, Japan.
  • Koba N; Research and Development, RaQualia Pharma Inc, 5-2 Taketoyo, Aichi 470-2341, Japan.
  • Sugiura A; Research and Development, RaQualia Pharma Inc, 5-2 Taketoyo, Aichi 470-2341, Japan.
  • Sudo M; Research and Development, RaQualia Pharma Inc, 5-2 Taketoyo, Aichi 470-2341, Japan.
Bioorg Med Chem Lett ; 25(2): 236-40, 2015 Jan 15.
Article en En | MEDLINE | ID: mdl-25499880

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Síndrome del Colon Irritable / Receptor Cannabinoide CB2 / Agonistas de Receptores de Cannabinoides Tipo de estudio: Diagnostic_studies / Prognostic_studies Idioma: En Revista: Bioorg Med Chem Lett Asunto de la revista: BIOQUIMICA / QUIMICA Año: 2015 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Síndrome del Colon Irritable / Receptor Cannabinoide CB2 / Agonistas de Receptores de Cannabinoides Tipo de estudio: Diagnostic_studies / Prognostic_studies Idioma: En Revista: Bioorg Med Chem Lett Asunto de la revista: BIOQUIMICA / QUIMICA Año: 2015 Tipo del documento: Article